Renate Schmelz1, Stephan Miehlke2, Christian Thiede3, Stefan Brueckner3, Monic Dawel4, Matthias Kuhn5, Agnes Ruskoné-Formestraux6, Manfred Stolte7, Christina Jentsch4, Jochen Hampe3, Andrea Morgner8. 1. Medical Departement 1, University Hospital Carl Gustav Carus, Technical University, Fetscherstr. 74, 01307, Dresden, Germany. renate.schmelz@uniklinikum-dresden.de. 2. Center for Digestive Diseases, Cooperation of Internal Medicine, Hamburg, Germany. 3. Medical Departement 1, University Hospital Carl Gustav Carus, Technical University, Fetscherstr. 74, 01307, Dresden, Germany. 4. Department of Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany. 5. Institute for Medical Informatics and Biometry, Technical University, Dresden, Germany. 6. Service de Gastroentérologie, St Antoine Hospital, Paris, France. 7. Institute for Pathology, Hospital Kulmbach, Kulmbach, Germany. 8. University Hospital Hamburg-Eppendorf, Center for Oncology and University Cancer Center Hamburg (UCCH), Hamburg, Germany.
Abstract
BACKGROUND: In Helicobacter pylori (H. pylori) positive stage I gastric low-grade MALT lymphoma, eradication is the accepted first-line therapy. The role of eradication therapy in lymphoma > stage IE is still unclear. However, about 20% of patients show persistent lymphoma following successful eradication or primary H. pylori-negative lymphoma. A prospective study for salvage radiation therapy with standard 36 Gy in comparison to a reduced dose of 25.2 Gy is still missing. METHODS: A prospective, multicentre study investigated the efficacy of eradication in H. pylori-positive gastric low-grade MALT lymphoma stages IE and II1E (HELYX I). Refractory lymphoma or H. pylori-negative patients were treated in a prospective, randomised, multicentre, phase II study to receive either 25.2 Gy or 36 Gy radiotherapy (HELYX II). RESULTS: 102 patients (3 drop outs) were included in HELYX I: 75/99 (75.8%) showed complete remission after a median of 2.8 months. 18 (18.2%) had partial remission (PR) and 6 (6.0%) no change (NC). 29 patients (7 drop outs) were randomized in HELYX II (7 primarily H. pylori-negative, 15 patients from HELYX I with refractory disease after eradication). All patients achieved stable CR irrespective of radiation dose. Both presence of the t(11,18) translocation (OR 9.0, p = 0.01) and monoclonality of the tumour cells (OR 6.3, p = 0.006) were predictors for persistant lymphoma after eradication therapy. CONCLUSIONS: Most H. pylori-positive low grade gastric MALT lymphoma stage IE and II1E respond with stable CR after eradication therapy. In patients with refractory disease or H. pylori negative low grade gastric MALT lymphoma a dosage-reduced radiation therapy with 25.2 Gy is an effective standard dose in stage IE and II1E. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00154440.
RCT Entities:
BACKGROUND: In Helicobacter pylori (H. pylori) positive stage I gastric low-grade MALT lymphoma, eradication is the accepted first-line therapy. The role of eradication therapy in lymphoma > stage IE is still unclear. However, about 20% of patients show persistent lymphoma following successful eradication or primary H. pylori-negative lymphoma. A prospective study for salvage radiation therapy with standard 36 Gy in comparison to a reduced dose of 25.2 Gy is still missing. METHODS: A prospective, multicentre study investigated the efficacy of eradication in H. pylori-positive gastric low-grade MALT lymphoma stages IE and II1E (HELYX I). Refractory lymphoma or H. pylori-negative patients were treated in a prospective, randomised, multicentre, phase II study to receive either 25.2 Gy or 36 Gy radiotherapy (HELYX II). RESULTS: 102 patients (3 drop outs) were included in HELYX I: 75/99 (75.8%) showed complete remission after a median of 2.8 months. 18 (18.2%) had partial remission (PR) and 6 (6.0%) no change (NC). 29 patients (7 drop outs) were randomized in HELYX II (7 primarily H. pylori-negative, 15 patients from HELYX I with refractory disease after eradication). All patients achieved stable CR irrespective of radiation dose. Both presence of the t(11,18) translocation (OR 9.0, p = 0.01) and monoclonality of the tumour cells (OR 6.3, p = 0.006) were predictors for persistant lymphoma after eradication therapy. CONCLUSIONS: Most H. pylori-positive low grade gastric MALT lymphoma stage IE and II1E respond with stable CR after eradication therapy. In patients with refractory disease or H. pylori negative low grade gastric MALT lymphoma a dosage-reduced radiation therapy with 25.2 Gy is an effective standard dose in stage IE and II1E. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00154440.
Authors: Thomas Wündisch; Christian Thiede; Andrea Morgner; Astrid Dempfle; Annette Günther; Hongxiang Liu; Hongtao Ye; Ming-Qing Du; Theo D Kim; Ekkehard Bayerdörffer; Manfred Stolte; Andreas Neubauer Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: Hongxiang Liu; Hongtao Ye; Agnes Ruskone-Fourmestraux; Daphne De Jong; Stefano Pileri; Christian Thiede; Anne Lavergne; Henk Boot; Giancarlo Caletti; Thomas Wündisch; Thierry Molina; Babs G Taal; Sabattini Elena; Togliani Thomas; Pier Luigi Zinzani; Andreas Neubauer; Manfred Stolte; Rifat A Hamoudi; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: C Thiede; T Wündisch; B Alpen; B Neubauer; A Morgner; M Schmitz; G Ehninger; M Stolte; E Bayerdörffer; A Neubauer Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Peter Koch; Andreas Probst; Wolfgang E Berdel; Normann A Willich; Gabriele Reinartz; Jens Brockmann; Rüdiger Liersch; Francisco del Valle; Hermann Clasen; Carsten Hirt; Regine Breitsprecher; Rudolf Schmits; Mathias Freund; Rainer Fietkau; Peter Ketterer; Eva-Maria Freitag; Margit Hinkelbein; Achim Heinecke; Reza Parwaresch; Markus Tiemann Journal: J Clin Oncol Date: 2005-08-29 Impact factor: 44.544
Authors: Richard W Tsang; Mary K Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Michael Crump; Bruce J Patterson Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-12 Impact factor: 7.038
Authors: Omran Saifi; Scott C Lester; William Rule; Bradley J Stish; Scott Stafford; Deanna H Pafundi; Liuyan Jiang; David Menke; Muhamad Alhaj Moustafa; Allison Rosenthal; Taimur Sher; Ayala Ernesto; Han W Tun; Bradford S Hoppe; Jennifer L Peterson Journal: Adv Radiat Oncol Date: 2021-05-08
Authors: Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich Journal: Cancers (Basel) Date: 2022-02-10 Impact factor: 6.639